It is therefore promising that the acute treatment with NLRP3 inhibitors such as MCC950 does not only lessen the neuroinflammation in IS and improve the post-stroke neurologic outcome but also reduce the incidence of AD after IS. The gene discussed is NLRP3; the disease is stroke disorder.